Exploring hybrid mRNA vaccine technology for lasting immunity to COVID-19

While COVID-19 vaccines have proven effective, the need for lasting immunity has prompted exploration beyond conventional approaches. Casey Nevins, Assistant Editor, Vaccine Insights, speaks with Magnus Hoffmann, Merkin Institute Fellow in the Merkin Institute for Translational Research at Caltech, about his work on developing a hybrid mRNA vaccine technology and its potential to address the limitations of current COVID-19 vaccines.

Please enter your email to access content Read now